Particle.news
Download on the App Store
5 ARTICLES
·
3d ago

CSL Secures VarmX Acquisition Option, Funding Phase 3 of Factor Xa Reversal Drug

The move channels post-restructuring investment into a late-stage program for reversing Factor Xa anticoagulants used by millions.

Image
The Phase III EquilibriX-S study will test the therapy in those on FXa DOACs. Credit: Gorodenkoff / Shutterstock.com.
Image
VarmX and CSL to collaborate in research deal worth up to $2.1bn

Overview

  • CSL agreed to pay $117 million upfront for an exclusive option to acquire VarmX, exercisable after reviewing Phase 3 results for VMX-C001.
  • CSL will fully finance the global Phase III EquilibriX-S study in patients on Factor Xa direct oral anticoagulants who need urgent surgery, and will cover manufacturing and other pre-launch work.
  • VarmX shareholders could receive up to $388 million in additional payments before a potential launch and as much as $1.7 billion tied to sales milestones if the drug reaches the market.
  • VMX-C001 is intended as a single-dose reversal for anticoagulants such as Eliquis and Xarelto, with a non-thrombogenic safety profile viewed as critical after concerns with Andexxa.
  • The companies cite FDA fast track status and an anticipated 2029 commercial timeline, contingent on positive Phase 3 data, option exercise, and regulatory approvals.